DE69321118D1 - Peptide und Proteine, Verfahren zur Ihren Herstellung und die Verwendung als Cholesterol-Annehmer - Google Patents

Peptide und Proteine, Verfahren zur Ihren Herstellung und die Verwendung als Cholesterol-Annehmer

Info

Publication number
DE69321118D1
DE69321118D1 DE69321118T DE69321118T DE69321118D1 DE 69321118 D1 DE69321118 D1 DE 69321118D1 DE 69321118 T DE69321118 T DE 69321118T DE 69321118 T DE69321118 T DE 69321118T DE 69321118 D1 DE69321118 D1 DE 69321118D1
Authority
DE
Germany
Prior art keywords
glu
lys
leu
pct
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69321118T
Other languages
English (en)
Other versions
DE69321118T2 (de
Inventor
Maryvonne Rosseneu
Robert Brasseur
Robert Deleys
Christine Labeur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of DE69321118D1 publication Critical patent/DE69321118D1/de
Application granted granted Critical
Publication of DE69321118T2 publication Critical patent/DE69321118T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69321118T 1992-06-12 1993-06-08 Peptide und Proteine, Verfahren zur Ihren Herstellung und die Verwendung als Cholesterol-Annehmer Expired - Fee Related DE69321118T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92401621 1992-06-12
PCT/EP1993/001444 WO1993025581A1 (en) 1992-06-12 1993-06-08 New peptides and proteins, process for their preparation and their use as cholesterol acceptors

Publications (2)

Publication Number Publication Date
DE69321118D1 true DE69321118D1 (de) 1998-10-22
DE69321118T2 DE69321118T2 (de) 1999-06-02

Family

ID=8211669

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69321118T Expired - Fee Related DE69321118T2 (de) 1992-06-12 1993-06-08 Peptide und Proteine, Verfahren zur Ihren Herstellung und die Verwendung als Cholesterol-Annehmer

Country Status (7)

Country Link
US (1) US5733879A (de)
EP (1) EP0644897B1 (de)
JP (1) JPH07507554A (de)
AT (1) ATE171192T1 (de)
CA (1) CA2137814A1 (de)
DE (1) DE69321118T2 (de)
WO (1) WO1993025581A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5344822A (en) * 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
US5652339A (en) * 1993-12-31 1997-07-29 Rotkreuzstiftung Zentrallaboratorium Method of producing reconstituted lipoproteins
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
EP0871713B1 (de) * 1995-11-09 2007-02-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) * 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
JP4644383B2 (ja) * 2001-05-11 2011-03-02 日本分光株式会社 タンパク質二次構造の面分布測定方法及び装置
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US7691965B2 (en) * 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
CA2486127C (en) 2002-05-17 2014-03-11 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
US7572771B1 (en) 2004-10-15 2009-08-11 The United States Of America As Represented By The Departments Of Health And Human Services Multi-domain amphipathic helical peptides and methods of their use
CN101115496B (zh) 2004-12-06 2012-03-07 加州大学评议会 改善微动脉的结构和功能的方法
MX2007013430A (es) * 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
MX2008015337A (es) * 2006-06-01 2009-11-26 Inst Cardiologie Montreal Metodo y compuesto para el tratamiento de estenosis valvular.
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8936787B2 (en) * 2008-04-15 2015-01-20 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptides promoting lipid efflux
NZ594516A (en) 2009-02-16 2012-12-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
US20110152112A1 (en) * 2009-12-23 2011-06-23 Artery Therapeutics, Inc. Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
JP5860052B2 (ja) * 2010-08-30 2016-02-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ テトラネクチン−アポリポタンパク質ａ−ｉ、それを含有する脂質粒子及びその使用
CN107074923B (zh) 2014-07-31 2021-08-03 Uab研究基金会 Apoe模拟肽及对清除血浆胆固醇的较高效力

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182364A (en) * 1990-02-26 1993-01-26 The Scripps Research Institute Polypeptide analogs of apolipoprotein E
US5168045A (en) * 1989-08-18 1992-12-01 The Scripps Research Institute Diagnostic systems and methods using polypeptide analogs of apolipoprotein e
US5177189A (en) * 1989-08-18 1993-01-05 The Scripps Research Institute Polypeptide analogs of Apolipoprotein E

Also Published As

Publication number Publication date
DE69321118T2 (de) 1999-06-02
JPH07507554A (ja) 1995-08-24
EP0644897A1 (de) 1995-03-29
ATE171192T1 (de) 1998-10-15
CA2137814A1 (en) 1993-12-23
EP0644897B1 (de) 1998-09-16
WO1993025581A1 (en) 1993-12-23
US5733879A (en) 1998-03-31
AU679180B2 (en) 1997-06-26
AU4324093A (en) 1994-01-04

Similar Documents

Publication Publication Date Title
DE69321118T2 (de) Peptide und Proteine, Verfahren zur Ihren Herstellung und die Verwendung als Cholesterol-Annehmer
Watterson et al. The complete amino acid sequence of the Ca2+-dependent modulator protein (calmodulin) of bovine brain.
TIMPL et al. The aminopropeptide of collagen
ATE352617T1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
ATE169304T1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
EP0821006A3 (de) Insulinderivate mit erhöhter Zinkbindung
PT975761E (pt) Interferao beta humano recombinante com solubilidade melhorada
DE69009476T2 (de) Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen.
DE69525544T2 (de) Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose
ATE364079T1 (de) Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung
DE69827262D1 (de) Penaeidine: antimikrobielle peptide aus krebstieren
DE3688324D1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
EP0297362A3 (de) Human-Aprotinin, dessen Lys-Rest in Position 15 gegen einen anderen protogenen Aminosäurerest ausgetauscht ist
DE69030920T2 (de) Verfahren zur herstellung von pai-2
FI956055A0 (fi) Tekijä VII:sta johdettuja peptidejä
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
ES2135398T3 (es) Compuesto y composiciones de inhibicion de la resorcion osea.
PT704527E (pt) Sequencias de adn que codificam precursores de insulina biossinteticos e processo para a preparacao de insulina
ATE224403T1 (de) Verwendung von kaseinfragmenten als wachstumerförderer
KR101036054B1 (ko) 단백질 폴리펩티드로부터 유도된 아실 리포아미노산류 및 리포펩티드류를 선택적으로 분리 정제하는 방법
ATE143974T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
ATE452139T1 (de) Peptid-köder zur herstellung von medikamenten, die für die prävention oder behandlung von autoimmunerkrankungen bzw. problemen, die mit dem auftreten von gegen exogene proteine gerichteten antikörpern in zusammenhang stehen, bestimmt sind
IT1251427B (it) Procedimento per preparare prodotti peptidici e/o proteinici arricchiti con amminoacidi legati in modo covalente

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee